Edition:
United Kingdom

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.53USD
2:59pm GMT
Change (% chg)

$0.14 (+3.30%)
Prev Close
$4.39
Open
$4.42
Day's High
$4.69
Day's Low
$4.39
Volume
155,917
Avg. Vol
297,905
52-wk High
$9.85
52-wk Low
$4.09

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $600.01
Shares Outstanding(Mil.): 90.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS

09 Jan 2018

BRIEF-Inovio Receives Milestone Payment From Medimmune

* INOVIO RECEIVES MILESTONE PAYMENT FROM MEDIMMUNE AS MEDI0457 AND CHECKPOINT INHIBITOR COMBINATION TRIAL IN HEAD AND NECK SQUAMOUS CELL CANCER ADVANCES TO PHASE 2 Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Inovio Enters License, Collaboration Agreement With Apollobio To Develop, Commercialize VGX-3100 In Greater China

* INOVIO ENTERS LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

02 Jan 2018

BRIEF-‍Inovio Pharma Cancer Vaccine Shows Promise In Preclinical Trial

* ‍INOVIO PHARMACEUTICALS SYNCON TERT CANCER IMMUNOTHERAPY COMBINED WITH CHECKPOINT INHIBITOR SYNERGISTICALLY SHRINKS TUMOR,IMPROVES SURVIVAL IN PRECLINICAL TUMOR MODEL​ Source text for Eikon: Further company coverage:

27 Nov 2017

BRIEF-Inovio pharmaceuticals reports 2017 third quarter financial results

* Inovio Pharmaceuticals reports 2017 third quarter financial results

08 Nov 2017

BRIEF-Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

* Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

02 Nov 2017

BRIEF-Inovio Pharma initiates immuno-oncology clinical study for glioblastoma

* Inovio Pharmaceuticals initiates immuno-oncology clinical study for glioblastoma in combination with Regeneron’S PD-1 inhibitor Source text for Eikon: Further company coverage:

01 Nov 2017

BRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine

* Inovio Pharmaceuticals Inc ‍reported on positive safety and immune response results from phase 1 trial of a vaccine against zika virus​

05 Oct 2017

BRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

* Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

18 Sep 2017

BRIEF-Inovio’s cancer immunotherapy slowed PSA rise and increased PSA doubling times in patients with recurrent prostate cancer

* Inovio’s cancer immunotherapy (ino-5150) slowed PSA rise and significantly increased psa doubling times in patients with recurrent prostate cancer

11 Sep 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $147.10 -0.26
Novartis AG (NOVN.S) CHF83.04 -0.34
Pfizer Inc. (PFE.N) $36.91 -0.03
Merck & Co., Inc. (MRK.N) $61.28 --
Sanofi SA (SASY.PA) €69.91 -3.04
GlaxoSmithKline plc (GSK.L) 1,359.20 +1.20
AstraZeneca plc (AZN.L) 5,051.00 +8.00

Earnings vs. Estimates